From Drugs of Abuse to Parkinsonism: The MPTP Mouse Model of Parkinson’s Disease - Drugs of Abuse: Neurological Reviews and Protocols - page 111

repeated exposures to combined paraquat and maneb: implications for Parkinson's
disease. J. Neurosci. 20, 9207-9214.
26. Feany, M. B. and Bender, W. W. (2000) A Drosophila model of Parkinson's
disease. Nature 404, 394-398.
27. Masliah, E., Rockenstein, E., Veinbergs, I., et al. (2000) Dopaminergic loss and
inclusion body formation in alpha-synuclein mice: implications for neurodegenera-
tive disorders. Science 287, 1265-1269.
28. Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., and
Kopin, I. J. (1983) A primate model of parkinsonism: selective destruction of
dopaminergic neurons in the pars compacta of the substantia nigra by N -methyl-
4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546-4550.
29. Gerlach, M. and Riederer, P. (1996) Animal models of Parkinson's disease: an
empirical comparison with the phenomenology of the disease in man. J. Neural
Transm. 103, 987-1041.
30. Eidelberg, E., Brooks, B. A., Morgan, W. W., Walden, J. G., and Kokemoor,
R. H. (1986) Variability and functional recovery in the N -methyl-4-phenyl-
1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience
18, 817-822.
31. Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., and Karluk,
D. (1999) Evidence of active nerve cell degeneration in the substantia nigra of
humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann.
Neurol. 46, 598-605.
32. Forno, L. S., DeLanney, L. E., Irwin, I., and Langston, J. W. (1993) Similarities
and differences between MPTP-induced parkinsonsim and Parkinson's disease.
Neuropathologic considerations. Adv. Neurol. 60, 600-608.
33. Kowall, N. W., Hantraye, P., Brouillet, E., Beal, M. F., McKee, A. C., and Ferrante,
R. J. (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of
baboons. NeuroReport 11, 211-213.
34. Heikkila, R. E., Hess, A., and Duvoisin, R. C. (1984) Dopaminergic neurotoxicity of
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224, 1451-1453.
35. Lau, Y.-S. and Fung, Y. K. (1986) Pharmacological effects of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine receptor system. Brain
Res. 369, 311-315.
36. Zuddas, A., Fascetti, F., Corsini, G. U., and Piccardi, M. P. (1994) In brown
Norway rats, MPP + is accumulated in the nigrostriatal dopaminergic terminals
but it is not neurotoxic: a model of natural resistance to MPTP toxicity. Exp.
Neurol. 127, 54-61.
37. Hamre, K., Tharp, R., Poon, K., Xiong, X., and Smeyne, R. J. (1999) Differential
strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) administration acts in an autosomal dominant fashion: quantitative
analysis in seven strains of Mus musculus . Brain Res. 828, 91-103.
38. Sonsalla, P. K. and Heikkila, R. E. (1986) The infl uence of dose and dosing
interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol.
129, 339-345.